CanaQuest Medical Corp.: CanaQuest Achieves Statistically Si

Drug Candidate, CQ-001 (cannabidiol "CBD" + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD.TORONTO, ON / ACCESSWIRE / December 8

Related Keywords

Canada , United States , United Kingdom , Toronto , Ontario , America , Steven Laviolette , Kostenloser Wertpapierhandel , W Mcintyre Burnham , Paul Ramsay , Ontario Brain Institute , Canaquest Medical Corp View , Global Health Pharma , University Of Toronto Temerty Faculty Medicine , Company Or Canaquest , Oils Product Development Company , Canaquest Medical Corp , Drug Candidate , Clinical Dose , Efficacy Study , Temerty Faculty , Clinical Study , Western University , Epilepsy Research Program , Canaquest Medical , Quest Medical , Post Traumatic Stress Disorder , Medical Cannabis , Botanical Oils Product Development Company , Global Health , Quest Medical Corp , Canaquest , Medical , Orp , Chieves , Statistically , Significant , Reduction , Seizures , Epilepsy , Ompared , Standard ,